BridgeBio Pharma (US.BBIO)
Capital Allocation Audit · Period: 2017 – 2026
Key Metrics
US.BBIO · YoY: 2026 Q1 vs 2025 Q1
| Metric | Value | YoY |
|---|---|---|
| FCF Conversion | 100.0% | → |
| ROE | - | → |
| Cash Conversion | - | → |
| D/E Ratio | - | → |
| Gross Margin | 94.9% | → |
US.BBIO (BridgeBio Pharma) | YoY: 2026 Q1 vs 2025 Q1 Metric Value YoY ---------------------------- FCF Conversion 100.0% → ROE - → Cash Conversion - → D/E Ratio - → Gross Margin 94.9% →
Key Metrics
US.BBIO (BridgeBio Pharma) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY----------------------------FCF Conversion 100.0% →ROE - →Cash Conversion - →D/E Ratio - →Gross Margin 94.9% →Audit Dimensions
Unlimited Companies
AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies